Bharat Parenterals Limited Q4 FY25 earnings call summary

Earnings call of 14 May 2025, summarised by AI from the filing.

Bharat Parenterals FY25 standalone revenue ₹318.7 cr (+19.8%); Innoxel guides FY26 milestone revenue ₹70-75 cr and operational break-even.

Key takeaways

1. US FDA Innoxel completed first US FDA inspection with one minor observation.
2. Risk CMO revenue timing depends on partner filings and approvals, not in company's hands.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)